MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

WBA

11.49

+0.26%↑

HQY

102.79

-1.67%↓

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

WBA

11.49

+0.26%↑

HQY

102.79

-1.67%↓

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

WBA

11.49

+0.26%↑

HQY

102.79

-1.67%↓

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

WBA

11.49

+0.26%↑

HQY

102.79

-1.67%↓

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

WBA

11.49

+0.26%↑

HQY

102.79

-1.67%↓

Search

Alkermes PLC

Closed

SectorHealthcare

28.99 1.29

Overview

Share price change

24h

Current

Min

28.23

Max

29.99

Key metrics

By Trading Economics

Income

-124M

22M

Sales

-123M

307M

P/E

Sector Avg

13.933

50.291

EPS

0.291

Profit margin

7.329

Employees

1,800

EBITDA

-168M

14M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+38.03% upside

Dividends

By Dow Jones

Next Earnings

23 Jul 2025

Market Stats

By TradingEconomics

Market Cap

-1B

4.8B

Previous open

27.7

Previous close

28.99

News Sentiment

By Acuity

50%

50%

163 / 380 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Alkermes PLC Chart

Past performance is not a reliable indicator of future results.

Related News

1 Jul 2025, 23:09 UTC

Earnings

Constellation Brands 1Q Profit, Sales Decline Amid Softer Consumer Demand -- Update

1 Jul 2025, 19:16 UTC

Acquisitions, Mergers, Takeovers

Sabadell Seeks Shareholder Approval of Nearly $4 Billion Sale of U.K. Unit to Santander

1 Jul 2025, 23:47 UTC

Market Talk

Nikkei May Fall Amid U.S. Tariff Uncertainty -- Market Talk

1 Jul 2025, 23:41 UTC

Market Talk

Gold Steady, Underpinned by U.S. Fiscal-Deficit Concerns -- Market Talk

1 Jul 2025, 22:23 UTC

Acquisitions, Mergers, Takeovers

James Hardie: Deal Represents Implied Value of $8.4 Billion

1 Jul 2025, 22:23 UTC

Acquisitions, Mergers, Takeovers

James Hardie: Cash and Stock Deal Implies $54.18 Per AZEK Share

1 Jul 2025, 22:21 UTC

Acquisitions, Mergers, Takeovers

James Hardie Completes Acquisition of AZEK

1 Jul 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

1 Jul 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

1 Jul 2025, 20:24 UTC

Earnings

Constellation Brands Earnings Miss as Consumers Cool on Alcohol -- Barrons.com

1 Jul 2025, 19:55 UTC

Market Talk

Oil Futures Resume Cautious Rally -- Market Talk

1 Jul 2025, 19:27 UTC

Market Talk

U.S. Natural Gas Futures Lose More Ground -- Market Talk

1 Jul 2025, 19:12 UTC

Market Talk

Dollar Little Changed as Tax-And-Spending Bill Advances -- Market Talk

1 Jul 2025, 19:01 UTC

Acquisitions, Mergers, Takeovers

Sabadell Seeks Shareholder Approval of Nearly $4B Sale of U.K. Unit to Santander

1 Jul 2025, 18:41 UTC

Acquisitions, Mergers, Takeovers

How DexCom, Insulet, and Amedisys Might Be Affected by Medicare Cuts -- Barrons.com

1 Jul 2025, 18:33 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

1 Jul 2025, 18:33 UTC

Market Talk

Gold Gains as Investors Look Ahead on Budget Bill -- Market Talk

1 Jul 2025, 18:32 UTC

Market Talk

Mexico Manufacturing PMIs Remain Weak in June -- Market Talk

1 Jul 2025, 18:22 UTC

Market Talk

Remittances to Mexico Down in May -- Market Talk

1 Jul 2025, 17:45 UTC

Market Talk

Seasonal Demand Supports Further Oil Gains -- Market Talk

1 Jul 2025, 17:01 UTC

Acquisitions, Mergers, Takeovers

Danone Completed Acquisition of Majority Stake in Kate Farms

1 Jul 2025, 16:55 UTC

Earnings

10 European Dividend Stocks That Could Beat Their U.S. Counterparts -- Barrons.com

1 Jul 2025, 16:27 UTC

Market Talk

Trade Concerns Ease in Bank of Mexico Survey -- Market Talk

1 Jul 2025, 16:25 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Home Depot's GMS Buy Unlocks New Vertical Adjacent to SRS -- Market Talk

1 Jul 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

1 Jul 2025, 15:48 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Home Depot's Offer for GMS Unlikely to Be Beat -- Market Talk

1 Jul 2025, 15:46 UTC

Market Talk

Global Equities Roundup: Market Talk

1 Jul 2025, 15:46 UTC

Market Talk

Amazon Seen With Improved Logistics Ahead of Longer Prime Day -- Market Talk

1 Jul 2025, 14:54 UTC

Market Talk

Thales Expected to Stick to This Year's Sales Guidance -- Market Talk

1 Jul 2025, 14:49 UTC

Market Talk

Platinum Prices Extend Rally on China Demand, Supply Worries -- Market Talk

Peer Comparison

Price change

Alkermes PLC Forecast

Price Target

By TipRanks

38.03% upside

12 Months Forecast

Average 40 USD  38.03%

High 46 USD

Low 30 USD

Based on 12 Wall Street analysts offering 12 month price targets forAlkermes PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

12 ratings

8

Buy

4

Hold

0

Sell

Technical Score

By Trading Central

27.95 / 30.91Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Strong Bullish Evidence

Sentiment

By Acuity

163 / 380 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.